Scilex Holding is a commercial non-opioid pain company whose residual equity now prices a recapitalization race rather than a product cycle. Management states substantial doubt about the ability to continue as a going concern after the mid-year print. Cash sat under one million against an operating franchise that still ships three approved products. The debate is whether any of the unsigned paper recaps fund before the senior Oramed clock comes due.
The quarter's operating story is a Japan-sourced inventory delay on ZTlido that pulled the core patch below the year-ago run rate. Newer migraine and gout liquids are growing off a small base and do not replace the lost patch sales. The larger hole in the half is not cost of goods. It is mark-to-market damage on Datavault equity, digital-asset holdings, and fair-value debt instruments that turned a painful operating loss into a triple-digit net loss.
The September Oramed extension and the Kazakhstan iHolding term sheet are the two documents that decide whether common equity remains a call option or a claim in a creditor process. A closed iHolding check at the advertised fifteen-dollar print would recapitalize the parent and dilute the existing float in one step. An unsigned sheet plus another missed amortization leaves the listing and the residual claim exposed. Does any funded close arrive before cash and covenant slack run out?